4-(4-(2-Aminopyrimidin-5-yl)-6-morpholino-1,3,5-triazin-2-yloxy)-N,N'-dimethylbenzamide

ID: ALA4789524

PubChem CID: 72950262

Max Phase: Preclinical

Molecular Formula: C20H22N8O3

Molecular Weight: 422.45

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CN(C)C(=O)c1ccc(Oc2nc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cc1

Standard InChI:  InChI=1S/C20H22N8O3/c1-27(2)17(29)13-3-5-15(6-4-13)31-20-25-16(14-11-22-18(21)23-12-14)24-19(26-20)28-7-9-30-10-8-28/h3-6,11-12H,7-10H2,1-2H3,(H2,21,22,23)

Standard InChI Key:  PDGYXVSGGSRTIY-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 31 34  0  0  0  0  0  0  0  0999 V2000
   17.1637   -5.3241    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.1626   -6.1436    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8706   -6.5526    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.5803   -6.1432    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5775   -5.3205    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   17.8688   -4.9152    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.4564   -6.5519    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0401   -7.3665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.7525   -7.7755    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   16.4571   -7.3658    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8648   -4.1037    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.5731   -3.6942    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.5726   -2.8806    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.8655   -2.4703    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.1572   -2.8798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.1561   -3.6996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.0412   -6.5484    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   15.7473   -6.1370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.2886   -6.5506    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   19.9957   -6.1409    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.7007   -6.5488    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4073   -6.1398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   21.4065   -5.3218    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   20.6931   -4.9144    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   19.9895   -5.3258    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.1130   -4.9111    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   22.8219   -5.3177    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   22.1106   -4.0939    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   22.8242   -6.1348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   23.5284   -4.9070    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.3327   -7.7755    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7 18  2  0
 17  8  2  0
  8  9  1  0
  9 10  2  0
 10  7  1  0
  2  7  1  0
 11 12  1  0
 11 16  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  1  0
  6 11  1  0
 17 18  1  0
  4 19  1  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 24  1  0
 24 25  2  0
 25 20  1  0
 23 26  1  0
 26 27  1  0
 26 28  2  0
 27 29  1  0
 27 30  1  0
  8 31  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4789524

   4-[[4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]-N,N-dimethylbenzamide

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 422.45

Molecular Weight (Monoisotopic): 422.1815

AlogP: 1.24

#Rotatable Bonds: 5

Polar Surface Area: 132.48

Molecular Species: NEUTRAL

HBA: 10

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 3.26

CX LogP: 1.89

CX LogD: 1.89

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.64

Np Likeness Score: -1.59

References

1. Mahajan D,Sen S,Kuila B,Sharma A,Arora R,Sagar M,Mahapatra AR,Gawade LB,Dugar S.  (2020)  Discovery and Development of SPR519 as a Potent, Selective, and Orally Bioavailable Inhibitor of PI3Kα and mTOR Kinases for the Treatment of Solid Tumors.,  63  (19): [PMID:32897703] [10.1021/acs.jmedchem.0c01061]

Source

Source(1):

• Scientific Literature